Dosing has begun in a new regimen of the HEALEY ALS platform trial, its ninth, which is testing the oral therapy NUZ-001 for ...

Insmed has launched a first-in-human Phase 1 trial testing its experimental ALS gene therapy INS1202 in people with the disease.

Positive data from EXPERTS-ALS could accelerate RT1999 towards a registration trial; RT1999 to be presented as a poster ...

AcuraStem, a patient-based biotechnology company developing disease-modifying therapies for amyotrophic lateral sclerosis (ALS), today announced it has received a two-year research grant from Target ...

USI hosts Illuminate ALS on March 29 with a film screening, Dr. Richard Bedlack’s presentation, and resources for those affected by ALS.

The U.S. Congress greenlit a historic $315 million in federal ALS research funding for 2026 amid Rare Disease Month, spotlighting biotech progress like VectorY Therapeutics' first patient dosing in ...

Allowing people with disabilities to talk by just thinking about a word, that's what UC Davis researchers hope to accomplish with new cutting-edge technology. It can be a breakthrough for people with ...

Neuralink has reached another milestone in brain-computer interface (BCI) technology, with ALS patient Nick Wray successfully using his thoughts to control a robotic arm. The demonstration, part of ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Researchers have found that patients with amyotrophic lateral sclerosis have ...

Researchers have revealed that blood lactate is a key biomarker that can predict physical outcomes and prognosis in patients ...

Verneeda Moore, an ALS patient, is using new eye-gaze technology to control her wheelchair at Novant Health’s ALS Clinic. The Tobii Dynavox technology allows Moore to communicate and navigate ...